2022年12月8日

Share Generate Biomedicines宣布，他们在同行评审期刊《免疫学前沿》(Frontiers in Immunology)上发表了数据，证明了该公司的技术平台在生成重新浮出水面的蛋白质方面的力量，这可能为为治疗选择有限的疾病创造新的治疗方法提供了一种手段。雷竞技推荐码怎么获得“蛋白质是生物机器——马达、传感器——让一切运转起来。该研究表明，该公司的计算蛋白质设计方法能够产生高度工程化的大肠杆菌l -天冬酰胺酶(ASN)变体，在维持酶功能的同时，显著减少与抗药物抗体的结合，减轻动物模型中的超敏反应。通过重新表面的蛋白质，Generate可能能够减少先前对蛋白质疗法的免疫的影响。“蛋白质是生物机器——马达、传感器——让一切运转起来。我们现在正在设计这些机器来驱动所需的生物任务，有可能治疗一系列疾病，”Generate的首席执行官Mike Nally说。“这些数据进一步证明了我们集成的机器学习和湿实验室方法的价值。这项研究强调了蛋白质设计在创造新型疗法方面的潜力，也是我们设计降低免疫反应疗法的努力的一部分。“许多生物疗法的最佳使用受到抗药物抗体和超敏反应的限制，这可能会影响疗效和对需要治疗的患者的治疗能力。”我们重新表面蛋白质的能力代表了一种帮助防止抗药物抗体负面影响的方法; we believe the resurfacing approach will be generalizable and may facilitate the development of new treatments for which additional options are urgently needed,” commented Alex Snyder, M.D., Generate’s Chief Medical Officer. Related Posts In the past, protein engineering has been costly as well as time- and labor-intensive and had limited capacity. The efficient and effective computational design of therapeutic proteins in this study has recently become feasible due to simultaneous innovations in computational processing power, machine learning approaches, and high-throughput methods for producing and evaluating novel proteins. Previous attempts to modify ASN using traditional approaches resulted in mutants with up to eight modifications, according to a 2014 article in The Journal of Biological Chemistry. In this study, however, the authors demonstrate the generation of functional ASNs with up to 58 mutations. These high levels of mutations represent a significant advancement in our ability to design complex proteins to meet multiple objectives, such as maintenance of function and reduction in immunogenicity. Because protein re-surfacing has many potential applications in oncology, ASN, used in standard-of-care regimens for Acute Lymphoblastic Leukemia (ALL), was selected as a clinically relevant biotherapeutic. Its use is critical to achieving an optimal clinical response, but is often limited due to the body’s immune response against it in the form of anti-drug antibodies (ADAs). Generate partnered with researchers at Dana-Farber Cancer Institute to assess the impact of re-surfacing on ADAs from ALL patients and demonstrated significantly reduced binding. This re-surfacing approach could be used to develop other novel protein treatment options for proteins hindered by these unwanted immune responses in patients.